Page 65 - Marcus News Today

Hancock Whitney Corp purchased a new stake in Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,736 shares of the company’s stock, valued at approximately $263,000. Several other hedge funds and other institutional investors also […]

CHICAGO - - Associated Bank announces the promotion of Marcus Harris to the role of vice president, relationship manager in Commercial Real Estate. He is responsible for originating real estate loans... | April 25, 2023

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the... | April 25, 2023

The collection and customer activation embody the Italian designer's unique expression of his brand amplified through the reimagined awards platform DALLAS, April 20, 2023 /PRNewswire/

- Oral Presentation to Highlight Efficacy and Specificity of ARCUS Nucleases for Potential Treatment of Chronic Hepatitis B ... | April 20, 2023

Oral Presentation to Highlight Efficacy and Specificity of ARCUS Nucleases for Potential Treatment of Chronic Hepatitis B Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company

An owner of Dominion Voting Systems spoke about the company’s strategy that led Fox to agree to a $787.5 million defamation settlement.

Already positive, the research from JP Morgan and its analyst Marcus Diebel still consider the stock as a Buy opportunity. The target price remains set at EUR 27. | April 19, 2023

In a research note published by Marcus Diebel, JP Morgan advises its customers to buy the stock. The target price is reduced from EUR 65 to EUR 63. | April 18, 2023

Stock price falls as bank reports lower earnings and a $470m loss on the sale of Marcus loans